Wearable HRV for Women: What Oura, WHOOP, and Apple Watch Actually Mean in Perimenopause

She opened her Oura app and saw the number: 28. Two years ago it was 52. She is 47, in perimenopause, sleeping badly, having hot flashes at night. The app showed a red dot. Her readiness score was 54. She searched online and read that low HRV indicates heart disease. She scheduled a cardiology appointment.

She was right to schedule the appointment. Not because 28 means heart disease, it does not necessarily. But because the trend and the context are clinically meaningful, and she does not have the framework to interpret them without guidance.

What wearable HRV actually measures

Heart rate variability is the variation in time between consecutive heartbeats. A heart rate of 60 bpm does not mean one beat every exactly one second. The intervals between beats vary, sometimes 950 milliseconds, sometimes 1100 milliseconds. HRV quantifies this variation.

Higher variation (higher HRV) reflects greater autonomic flexibility, the parasympathetic nervous system (vagal tone) is actively modulating the heart rate, producing variation. Lower variation reflects reduced vagal tone and higher sympathetic dominance , the heart rate becomes more metronomically constant at the expense of autonomic adaptability.

Consumer wearables measure HRV in the brief window after you wake and while sleeping, primarily using photoplethysmography (PPG), optical sensors that measure pulse wave variation through the skin. These measurements correlate with but do not perfectly replicate clinical ECG-derived HRV measurements, which are considered the gold standard. 3 / Early

The numbers mean different things on different devices, calculated using different algorithms (RMSSD, SDNN, pNN50). Oura and WHOOP primarily report RMSSD-derived values. Apple Watch reports a different metric. Do not compare absolute numbers between devices.

How the menstrual cycle changes HRV

The predictable cycle-phase variation in HRV is one of the most important pieces of context missing from consumer wearable interpretation for women.

Follicular phase (approximately days 1-14 from first day of period): Estrogen rises through this phase. Estrogen has direct effects on autonomic nervous system balance: it enhances vagal efferent activity (the parasympathetic signals that travel through the vagus nerve to the heart), increases baroreflex gain (the sensitivity of the blood pressure-heart rate feedback loop), and reduces sympathetic tone. These effects produce higher HRV during the follicular phase, the best HRV readings of the cycle for most women. 4 / Promising

Ovulation (approximately day 14): A brief spike in estrogen around ovulation may produce a brief HRV peak before progesterone rises.

Luteal phase (approximately days 14-28): Progesterone rises. Progesterone has mild sympathomimetic effects and increases resting heart rate by 5-10 bpm above follicular-phase baseline (this is physiologically normal). HRV falls 5-20% compared to the follicular phase. Some women show a more pronounced luteal-phase HRV dip, particularly in the late luteal phase before menstruation.

PMS / late luteal phase: Women with significant premenstrual symptoms often show the lowest HRV of their cycle in the 3-5 days before menstruation, coinciding with the rapid drop in both estrogen and progesterone that precedes the period.

The clinical implication: a woman who checks her wearable’s weekly HRV average and notices it is “low” without knowing she is in the late luteal phase may be observing normal physiology rather than a problem. Tracking HRV against cycle phase over 2-3 months reveals the personal pattern.

HRV in perimenopause: reading the trend, not the number

As estrogen declines in perimenopause, two processes converge to lower HRV:

Direct autonomic effect. Estrogen’s parasympathomimetic effects diminish with its decline. The vagal tone that estrogen was maintaining drops. The sympathetic-parasympathetic balance shifts. 4 / Promising

Sleep disruption amplification. Nocturnal hot flashes interrupt the overnight sleep architecture that normally allows parasympathetic recovery and HRV restoration. A woman with 8 nocturnal hot flashes per night is losing the majority of her slow-wave sleep, the sleep stage where parasympathetic dominance is highest and where HRV restoration primarily occurs. Each week of poor sleep compounds the autonomic deficit.

The SWAN (Study of Women’s Health Across the Nation) study documented that HRV declines significantly and more steeply in the menopausal transition period than age-matched predictions would suggest, the menopausal transition itself accelerates the autonomic aging that estrogen was partially restraining.

What the trend can tell you:

• Gradual sustained decline over months to years, coinciding with perimenopause onset: Estrogen-withdrawal autonomic change. Clinically meaningful signal, especially if accompanied by worsening sleep and hot flash frequency.

• Sudden sustained drop (over days to weeks) without clear explanation: May indicate sleep apnea development (a common and underdiagnosed condition in perimenopausal women), thyroid dysfunction, iron deficiency anemia, or a cardiac cause. Warrants clinical evaluation.

• Short-term variation (2-5 day dips): Normal. Associated with illness, poor sleep nights, alcohol, high training load, or late luteal phase.

• Recovery after improved sleep or alcohol reduction: Confirms that sleep and alcohol are driving the reading, clinically informative about modifiable factors.

Hot flashes as acute HRV confounders

One of the most underappreciated sources of HRV misinterpretation in perimenopausal women is the hot flash event itself. A hot flash is not merely a subjective experience of heat — it is an acute autonomic event driven by a sudden drop in the thermoregulatory set-point, triggering a rapid sympathetic discharge that produces peripheral vasodilation, sweating, and a transient surge in heart rate. 4 / Promising

During an active hot flash, HRV drops acutely. Sympathetic activation suppresses vagal tone in real time, and the heart rate variability metric on your wrist reflects exactly this: the interval-to-interval variation narrows as the sympathetic nervous system takes over. An HRV reading captured during or immediately after a hot flash is not a resting baseline — it is a snapshot of an acute autonomic stress response.

This creates a specific interpretation problem for wearable users who take spot-check HRV readings during the day or who wear their devices loosely at night. If a hot flash occurs during the brief morning window that Oura or WHOOP uses to establish its overnight HRV summary, that reading will reflect the hot flash’s sympathetic surge rather than the true overnight parasympathetic recovery average.

What this means practically:

• A low wearable HRV reading taken on a night with multiple nocturnal hot flashes does not necessarily indicate a new cardiac problem or a fundamentally lower baseline — it may be recording the autonomic imprint of vasomotor events.
• Comparing a low-hot-flash week to a high-hot-flash week in the HRV trend will typically show a clear correlation: more hot flashes produce lower nightly HRV, both because the events themselves cause acute HRV dips and because the resultant sleep fragmentation prevents overnight autonomic recovery.
• An apparent improvement in HRV after starting a therapy for hot flash suppression (MHT, fezolinetant, SSRIs) may in part reflect the removal of acute vasomotor HRV confounders, not only a direct autonomic effect of the therapy.

If your wearable logs hot flash events (the Oura ring can capture skin temperature spikes coinciding with vasomotor events), reviewing HRV alongside the hot flash log gives a much cleaner signal than HRV alone. A clinician looking at this paired data can distinguish between a woman whose HRV is low primarily because of nocturnal vasomotor events versus one whose HRV has declined independently of acute hot flash timing.

What different devices actually capture

Oura Ring: Primarily measures HRV during sleep. Provides RMSSD-based overnight values. Good trend tracking across weeks and months. The readiness score combines HRV, resting heart rate, and sleep duration into a single metric. For perimenopausal women: the readiness score will show the lowest values during the worst hot flash nights and improve with sleep improvement. Provides decent cycle-phase tracking if menstrual cycle dates are entered.

WHOOP: Measures HRV during sleep, provides RMSSD-based values. Strong focus on recovery, the WHOOP “strain” and “recovery” framework is useful for tracking overtraining. Less cycle-aware by default than Oura.

Apple Watch: Measures a different HRV metric (SDNN, which includes longer intervals) rather than RMSSD-focused overnight measurement. Less directly comparable to research HRV literature. The irregular rhythm notification (for AF detection) is a separate, clinically relevant feature that photoplethysmography can detect intermittent AF with reasonable sensitivity. 3 / Early

Garmin: Strong overnight HRV tracking with RMSSD. Good cycle tracking in women’s health feature.

Sleep architecture and nocturnal HRV

Wearable HRV readings captured during sleep are substantially more clinically informative than daytime or spot-check readings. This is not merely a convention — it reflects the underlying physiology of autonomic regulation.

During slow-wave sleep (also called N3 or deep sleep), parasympathetic tone reaches its daily peak. The vagus nerve is most active, sympathetic activity is suppressed, and HRV reaches its highest values of the 24-hour cycle. During REM sleep, the pattern is more complex: REM is associated with both high vagal tone and episodic sympathetic bursts, producing characteristic HRV variability within the sleep stage itself. During light sleep (N1 and N2), HRV sits between these extremes. During waking activity, sympathetic tone dominates and HRV is lower and more reactive to movement, stress, and posture. 5 / Solid

Consumer devices have converged on measuring HRV during sleep because this removes most of the noise: movement artifact, postural effects, cognitive engagement, and real-time emotional reactivity all suppress HRV and inflate apparent variability when readings are taken while awake. The overnight reading represents the most stable, reproducible autonomic signal that a wearable can capture.

Why this matters in perimenopause specifically:

Nocturnal hot flashes preferentially disrupt slow-wave sleep. The arousal triggered by a vasomotor event tends to pull women out of N3 sleep, with resultant sleep fragmentation that accumulates over weeks and months of poor nights. The consequence for HRV is that the highest-value sleep stage — the one responsible for the majority of overnight parasympathetic recovery — is repeatedly interrupted. A woman tracking her overnight HRV through a period of worsening nocturnal hot flashes is watching, in real time, the erosion of her slow-wave sleep autonomic recovery.

How to access sleep-phase HRV on consumer devices:

• Oura: The Oura app provides an HRV curve within the sleep detail view, showing how HRV varies across sleep stages through the night. Look for the elevation in HRV that typically corresponds to deep sleep periods. A flattened HRV curve with no clear deep-sleep peak is a sign of significantly disrupted slow-wave sleep.
• WHOOP: The WHOOP app provides sleep stage breakdowns alongside recovery metrics. Users can observe whether HRV peaks align with the slow-wave sleep windows.
• Garmin: Garmin’s Health Snapshot and sleep analytics provide overnight HRV alongside sleep staging, with trend data available in Garmin Connect.
• Apple Watch: Sleep-related HRV data is accessible through the Health app under Heart Rate Variability, but Apple Watch samples HRV periodically during sleep rather than providing a continuous curve — the resolution is lower than Oura or WHOOP.

The clinical takeaway: if your clinician asks about your HRV, providing the overnight trend data from a device that measures sleep-phase HRV is more informative than a daytime spot-check number. A 3-month trend of overnight HRV alongside the device’s sleep-stage data tells a more complete story than any single data point.

What wearables cannot tell you

Consumer HRV cannot detect:

Structural heart disease. A woman with significant coronary artery disease, HFpEF, or valvular disease may have normal-appearing wearable HRV between events. HRV reflects autonomic function, not the state of the coronary arteries or cardiac structure.

Blood pressure. Wrist-based blood pressure measurement in current consumer devices is not clinically validated. Elevated blood pressure, including nocturnal hypertension or morning blood pressure surges , is not visible in HRV data.

Atrial fibrillation reliably. Photoplethysmography-based AF detection has a meaningful false-positive rate, particularly in women with irregular heart rate patterns from other causes (frequent PVCs, supraventricular ectopy). An irregular rhythm notification should prompt clinical evaluation with an ECG, not self-diagnosis.

Microvascular coronary dysfunction. Women with ANOCA and microvascular dysfunction often show normal HRV because their condition does not impair autonomic function at rest, it impairs coronary microvascular response to demand.

How to use the data at a clinical appointment

Bring trend data, not today’s number. A six-month HRV trend graph alongside a calendar of known events (cycle phases, illness, high-stress periods, hot flash severity changes) provides clinically useful context that a single value does not.

Specific information to bring:

• 3-6 month HRV trend from the wearable’s export function
• Average HRV during your follicular phase versus luteal phase (if trackable)
• Whether HRV correlates with hot flash frequency/sleep quality
• Any sudden sustained drops and what coincided with them
• Any irregular rhythm notifications and the dates they occurred

The conversation to have: “My HRV has declined from approximately 48 to 32 over 18 months, coinciding with worsening perimenopause symptoms and significant sleep disruption from nocturnal hot flashes. I want to understand whether this represents the expected autonomic effect of estrogen withdrawal, whether it warrants any additional cardiac evaluation, and what I can do to improve it.”

When a low HRV reading warrants clinical evaluation

Not every low HRV reading in a perimenopausal woman requires a cardiology appointment. The challenge is distinguishing the expected autonomic changes of the menopausal transition from patterns that warrant investigation.

Expected perimenopausal variation — monitoring appropriate, not urgent:

A gradual decline in HRV baseline over 12-24 months coinciding with the onset of other perimenopausal symptoms (irregular cycles, increasing hot flash frequency, worsening sleep) represents the expected autonomic trajectory of estrogen withdrawal. This pattern does not independently mandate urgent cardiac evaluation, though it provides appropriate context for a routine clinical visit where cardiovascular risk factors can be assessed.

Short-term fluctuations of 10-20% below personal baseline lasting 2-7 days, particularly when associated with identifiable causes (illness, increased alcohol intake, high-stress period, worsened hot flash frequency, travel), are within the expected range of normal autonomic variation.

Patterns that warrant clinical evaluation:

• Sudden sustained drop of 25-30% or more below personal baseline persisting beyond 2 weeks, without a clear explanation. This pattern — unlike the gradual perimenopausal decline — may indicate a new medical condition. Differential includes new or worsening sleep apnea (common and underdiagnosed in perimenopausal women), thyroid dysfunction, iron deficiency anemia, a new cardiac arrhythmia, or worsening heart failure if already diagnosed.

• Sustained HRV decline accompanied by new or worsening exertional symptoms. Dyspnea with exertion, chest pressure, or palpitations that coincide with a declining HRV trend warrant cardiac evaluation regardless of HRV values. HRV is not a sensitive marker for ischemic disease, and a woman can have significant coronary artery disease or microvascular dysfunction with a normal HRV.

• Irregular rhythm notifications from the wearable. Any device-generated flag for possible atrial fibrillation warrants an ECG regardless of what the surrounding HRV data looks like. Do not conclude that an irregular rhythm notification is a false positive because your overall HRV appears normal.

• Low HRV accompanied by low resting heart rate in a woman not engaged in endurance training. While high endurance athletes often show low HRV with low resting heart rate (athletic adaptation), in non-athletes this combination may reflect hypothyroidism, medication effects (beta-blockers, digoxin), or conduction system disease.

The useful clinical framing is: wearable HRV in perimenopause provides longitudinal trend data that, in context, can support or clarify a clinical picture. It does not replace clinical evaluation when symptoms warrant it. A woman who is symptomatic should seek evaluation; her wearable data is supporting evidence for that visit, not a substitute for it.

What actually improves HRV in perimenopause

Aerobic exercise: The single highest-yield intervention. Regular moderate-intensity aerobic exercise (150+ minutes per week) is the most evidence-based way to improve vagal tone and HRV. The effect is reproducible and occurs within weeks of consistent training. 5 / Solid

Sleep protection: Each full night of uninterrupted sleep allows overnight HRV restoration that fragmented sleep cannot provide. Treating the hot flashes that fragment sleep, with MHT, fezolinetant, or SSRIs/SNRIs , improves HRV by improving sleep quality rather than directly.

Alcohol elimination: Alcohol reduces HRV acutely (day of) and chronically (persistent chronic use). Eliminating or substantially reducing alcohol produces measurable HRV improvement within 2-4 weeks in most women.

Magnesium glycinate: Magnesium supports parasympathetic nervous system function through GABA receptor modulation. Supplementation in deficient women improves HRV in some trials. A reasonable trial in perimenopausal women with low HRV and suspected magnesium insufficiency.

Stress exposure reduction: The autonomic nervous system recovers during periods of reduced demand. Scheduled HPA-axis recovery time, whether through deliberate rest, controlled exercise, or social connection , improves HRV in validated studies.

Related reading

For the autonomic context of perimenopausal cardiac symptoms: Hot Flashes Are Not Just Uncomfortable.

For the sleep disruption that suppresses HRV: Why Women Wake at 3am.

For the magnesium supplementation that supports autonomic function: Magnesium for Perimenopause: Which Form.